2. GPCR/G Protein Neuronal Signaling
  3. Orexin Receptor (OX Receptor)
  4. Orexin A (human, rat, mouse) (acetate)

Orexin A (human, rat, mouse) (acetate)  (Synonyms: Hypocretin-1 (human, rat, mouse) (acetate))

Cat. No.: HY-106224B Purity: 99.67%
COA Handling Instructions

Molarity Calculator

Orexin A (Hypocretin-1) (human, rat, mouse) acetate is a hypothalamic neuropeptide with analgesic properties (crosses the blood-brain barrier). Orexin A (human, rat, mouse) acetate is also an OX1R agonist that induces the expression of BDNF and TH proteins in SH-SY5Y cells in a time- and dose-dependent manner. Orexin A (human, rat, mouse) acetate can be used in studies of appetite regulation, neurodegenerative diseases and modulation of injurious messaging.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

Orexin A (human, rat, mouse) (acetate) Chemical Structure

Orexin A (human, rat, mouse) (acetate) Chemical Structure

Size Price Stock Quantity
5 mg USD 318 In-stock
10 mg USD 510 In-stock
25 mg USD 960 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

Other Forms of Orexin A (human, rat, mouse) (acetate):

Orexin A (human, rat, mouse) (acetate) Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Orexin A (Hypocretin-1) (human, rat, mouse) acetate is a hypothalamic neuropeptide with analgesic properties (crosses the blood-brain barrier). Orexin A (human, rat, mouse) acetate is also an OX1R agonist that induces the expression of BDNF and TH proteins in SH-SY5Y cells in a time- and dose-dependent manner. Orexin A (human, rat, mouse) acetate can be used in studies of appetite regulation, neurodegenerative diseases and modulation of injurious messaging[1][2][3].

In Vitro

Orexin A (human, rat, mouse) acetate (0.1, 1, 10, 100 nM; 24 h) increases the expression of BDNF in SH-SY5Y human dopaminergic neuroblastoma cells in a dose-dependent manner[1].
Orexin A (human, rat, mouse) acetate (1 nM; 1, 3, 6, 12, 24 h) increases the expression of BDNF, TH, and PI3K in a time-dependent manner in SH-SY5Y cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Orexin A (human, rat, mouse) (acetate) Related Antibodies

Western Blot Analysis[1]

Cell Line: SH-SY5Y cells
Concentration: 0.1, 1, 10, 100 nM
Incubation Time: 24 h
Result: Increased the expression of PI3K and TH in a dose-dependent manner.
Significantly induced BDNF expression at the dose of 1 and 10 nM.

Western Blot Analysis[1]

Cell Line: SH-SY5Y cells
Concentration: 1 nM
Incubation Time: 1, 3, 6, 12, 24 h
Result: Showed the expression of PI3K rapidly increased by 72.6 % as soon as 3 h, which maintained at high levels in the following 24 h.
Increased the protein level of BDNF and the increased rate was 44.8%, and the protein level of TH significantly increased at 12 h by 48.5%.
In Vivo

Orexin A (human, rat, mouse) acetate (300 ng/mouse; i.c.v.; single daily for 8 days) attenuates the loss of dopaminergic neurons and the decrease of tyrosine hydroxylase (TH) expression in the substantia nigra, normalized the striatal dopaminergic fibers, and prevents the depletion of dopamine and its metabolites in the striatum[1].
Orexin A (human, rat, mouse) acetate (10, 30 mg/kg; i.v.; single) shows to be analgesic in the carrageenan-induced thermal hyperalgesia model and PPQ-induced mouse abdominal constriction model[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male C57BL/6 mice (10-week-old; 22-26 g; MPTP-Induced Mouse Model of PD)[1].
Dosage: 300 ng/mouse
Administration: Intracerebroventricular injection; single daily for 8 days
Result: Reversed MPTP-induced motor impairments via OX1R and increased the protein expression of BDNF in nigral dopaminergic neurons.
Improved MPTP-induced impairments in spatial Learning and memory and protected dopaminergic neurons against MPTP-induced neurotoxicity.
Attenuated the reduction of dopaminergic neurons in the substantia nigra and restored the reduction of dopaminergic fibers in the striatum.
Animal Model: Female ICR mice (17-28 g; carrageenan-induced thermal hyperalgesia model)[2].
Dosage: 10, 30 mg/kg
Administration: Intravenous injection; single; 5 min pre-test
Result: Increased paw withdrawal latency to the thermal stimulus back to baseline levels.
Animal Model: Male ICR mice (17-20 g; phenyl-p-quinone (PPQ)-induced mouse abdominal constriction model)[2].
Dosage: 3, 10, 30 mg/kg
Administration: Intravenous injection; single; given immediately before PPQ
Result: Increased the latency to the first PPQ-induced constriction from 357.4 s (blank control group) to 500.3 s at 10 mg/kg and 594.5 s at 30 mg/kg.
Formula

C152H243N47O44S4.xC2H4O2
Appearance

Solid

Color

White to off-white

Sequence Shortening

{Glp}-PLPDCCRQKTCSCRLYELLHGAGNHAAGILTL-NH2 (Disulfide bridge: Cys6-Cys12, Cys7-Cys14)
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Sealed storage, away from moisture and light, under nitrogen

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)

Solvent & Solubility
In Vitro: 

H2O : ≥ 50 mg/mL

*"≥" means soluble, but saturation unknown.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Orexin A (human, rat, mouse) (acetate) Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Orexin A (human, rat, mouse) (acetate)Hypocretin-1 (human, rat, mouse) (acetate)Orexin Receptor (OX Receptor)Hypocretin ReceptorHCRT ReceptorPDparkinson’ s diseaseSH-SY5YanalgesicBDNFTHPI3KPKCInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Orexin A (human, rat, mouse) (acetate)
Cat. No.:
HY-106224B
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.